Immuneering
IMRX
32 hedge funds and large institutions have $172M invested in Immuneering in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.
162% more capital invested
Capital invested by funds: $65.7M → $172M (+$107M)
0.32% less ownership
Funds ownership: 46.04% → 45.71% (-0.32%)
14% less funds holding
Funds holding: 37 → 32 (-5)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$754K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$618K |
| 3 |
BlackRock
New York
|
+$535K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$533K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$263K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.81M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$1.08M |
| 3 |
Millennium Management
New York
|
-$940K |
| 4 |
Renaissance Technologies
New York
|
-$138K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$114K |
IMRX Hedge Fund Activity: Q3 2022 in Review
32 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q3 2022, worth a combined $172M — up 162% from $65.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IMRX and 5 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Geode Capital Management, adding an estimated $754K. The largest seller was T. Rowe Price Associates, cutting an estimated $3.81M.
- 32 institutional investors held Immuneering (IMRX) as of Q3 2022, down from 37 in Q2 2022.
- Funds reported $172M of Immuneering stock for Q3 2022, up 162% quarter-over-quarter.
- 5 funds opened new Immuneering positions in Q3 2022 and 10 closed out, a net change of -5 holders.
- The largest Immuneering buyer in Q3 2022 was Geode Capital Management, an estimated $754K added.
- The largest Immuneering seller in Q3 2022 was T. Rowe Price Associates, an estimated $3.81M sold.
Based on aggregated 13F filings for Q3 2022.